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MULTICELLULAR SPHEROIDS OF A549 AND A549-IRFP CELLS AS AN IN VITRO
MODEL OF LUNG CANCER
Abstract
By Xinyu Pei
University of the Pacific
2020
Lung cancer is the second most common cancer in both men and women around the
world, and 85% of it is non-small cell lung cancer (NSCLC). It is estimated that in 2020, there
will be 228,820 cases of lung cancer and 135,720 deaths from lung (American Cancer Society,
2020). The prognosis of lung cancer is poor (<10% 5-year survival rate for advanced NSCLC),
which can be partly attributed to limitations in bio-models that screen for drug candidates against
lung cancer.
Traditionally, the most commonly used in vitro method for screening therapeutic drugs is
monolayer cell cultures, which are reproducible, convenient and of low cost. However,
monolayer cell culture models are unable to reproduce many properties of in vivo solid tumors
such as the morphological features and the microenvironment including cellular heterogeneity,
cell-cell interactions, and gradients of oxygen, pH, and nutrients. Consequently, excessive
ineffective drug candidates would proceed to animal studies, which would prolong the time for
drug development and increase the overall cost of drug discovery.
In consideration of the foregoing, in vitro models of cancer based on three-dimensional
multicellular spheroids (MCS) have been developed in our group to characterize drug candidates
and drug delivery systems. Compared to monolayer cells, the multicellular spheroids can better
simulate drug penetration and drug resistance in solid tumors. Therefore, the multicellular
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spheroids represent a more clinically relevant in vitro model to evaluate the efficacy of
anticancer drugs.
This project aims to characterize MCS of lung cancer cells as an improved platform to
evaluate drug candidates against lung cancer. Cell viability assays on cisplatin, carboplatin,
gemcitabine, and doxorubicin have been conducted to compare the anticancer activities between
conventional monolayer cells and the corresponding MCS of human lung cancer cell lines, A549
and A549-iRFP (fluorescently labeled A549 cells). Higher concentrations of the tested
anticancer drugs is consistently needed to inhibit 50% the cell viability in MCS than the
corresponding monolayer cells of A549 and A549-iRFP.
Cycled dosing schedules based on guidelines for NSCLC from National Comprehensive
Cancer Network have been designed and used to treat A549-iRFP MCS. The A549-iRFP MCS
have been exposed to anticancer drugs either continuously, or in pulsed concentrations according
to the drugs’ pharmacokinetics (PK). The continuous drug exposure has been found to inhibit
more cell growth in MCS than the corresponding PK-mimetic drug exposure. Such phenomenon
would bring significant positive bias to the activity of many anticancer drug candidates during
their early discovery and development.
Taken together, MCS of A549 and A549 iRFP cells better represent the efficacy of
anticancer drugs in clinic than the monolayer. MCS can also be used to evaluate anticancer drug
candidates by pulsed drug exposure based on their pharmacokinetics, and by commonly used
cycled dosing regiments to better predict their efficacy in clinical settings.
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CHAPTER 1: INTRODUCTION
1.1.

Cancer and Anticancer Drug Development Process

Drug development is a long process where a potential new drug must be identified and
evaluated in preclinical studies which involves in vitro cell culture and in vivo animal studies.
Then the drug candidates must go through four phases of clinical trials before being approved by
the FDA. In theory, the preclinical studies at the early stages of drug discovery process should
improve the success rate of the clinical trials but in reality, the approval rate of anticancer drug is
exceptionally low despite of the promising preclinical results. A recent report given by
Biotechnology Innovation Organization (BIO) entitled “Clinical Development Success Rates
2006-2015” pointed out that oncology drug candidates had only 5.1% rate of success from phase
I compared to the success rate of 11.9% for drug candidates of all other indications (Thomas et
al., 2016). This low success rate of oncology drug candidates could be partially explained by the
preclinical cancer models that pharmaceutical companies use for the first-pass screening of the
drug candidates. The main strategy to select drug candidates in vitro is to evaluate their
activities in cultures of two-dimensional (2D) monolayer cells. It is only in recent years that
more sophisticated, three-dimensional (3D) cell cultures were introduced as an improved model
to screen anticancer drugs in vitro.
1.2.

Traditional in vitro Drug Screening in Monolayer Cell Culture

Monolayer cell culture is the most commonly used drug screening method in vitro.
Advantages of monolayer cell cultures include fast assessment, simplicity, convenience, good
reproducibility and low cost. However, this method does not reproduce many properties of solid
tumor in vivo. The monolayer cells have poor cell-cell interactions, poor cell-extracellular
interactions, negligible cancer cell heterogeneity, incorrect morphology and substantially
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different microenvironment. Consequently, a lot of unviable drug candidates have been
forwarded from such cell culture studies to further studies in vivo, which caused extensive waste
of time, money and experimental animals.
1.3.

Improved in vitro Drug Screening in Three-Dimensional Cell Culture

Because of the above-mentioned limitations of the monolayer cells, it is necessary to
reproduce 3D architecture of solid tumor to better understand the biology of cancer, and to better
identify anticancer drug candidates. 3D cell cultures can meet these needs and can be developed
into better platforms of in vitro drug screening. In 3D cell cultures, cells can be aggregated to
form clusters in a spheroid shape, which is called multicellular spheroid (MCS). In this way,
multicellular spheroids of cancer cells can be fabricated to mimic many more features of solid
tumors than monolayer cells in culture.
1.3.1. Morphological Features
Multicellular spheroids are cell aggregates with a three-dimensional structure that is more
similar to solid tumor in morphology than monolayer cells. Well-formed spheroids normally
show a spheroid shape under scanning electron microscope or a round shape under phase
contrast microscope. The MCS morphology of different cell lines vary; some form tight
spheroids while others form loose MCS (as shown in Figure 1).

Figure 1. Morphology of tight and loose MCS after 24h cultivation. (A, B). Highly compact
MCS formed by MCF7 and T-47D cells; (C, D) Loose MCS formed by MDA-MB-231 and
MDA-MB-361. Scale bar = 500 µm. (Andrea & Manfred, 2006).
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1.3.2. Hypoxia Microenvironment
Hypoxia is one of the hallmarks in solid tumors, where the oxygen level gradually
reduced from outer regions to inner areas. This occurs as a consequence of multiple factors,
including rapid oxygen consumption, increased diffusion distance from vasculature to cells,
irregular vascular geometry, and low oxygen capacity in blood (Hammond et al., 2014; Höckel
& Vaupel, 2001). Such an oxygen gradient can also be seen in MCS, as confirmed in many
studies using microelectrodes, ethidium-calcein staining, and/or measurements of hypoxia
inducible factor (HIF) and its downstream target gene, VEGF. (Bredel-Geissler, Karbach,
Walenta, Vollrath, & Mueller-Klieser, 1992; Riffle & Hegde, 2017; Zanoni et al., 2016). For
example, a 3.3-fold increase of HIF-1α level in MCS was detected compared with monolayer of
HeLa cells (Rodríguez-Enríquez et al., 2008). One possible reason for the oxygen gradient in
MCS would be that cells at the peripheral regions consumes most oxygen as it diffuses to inner
cells (Mueller-Klieser & Sutherland, 1982).
1.3.3. Altered Cell Metabolism
Cells normally obtain energy through oxidative phosphorylation under aerobic
environment, whereas in solid tumor, even in the presence of oxygen, energy is preferably
obtained from glycolysis, when lactate is generated as by-product (Vander Heiden, Cantley, &
Thompson, 2009; Warburg, 1956). This alteration of metabolism in solid tumors is known as the
Warburg. MCS also shows the Warburg effect by the increased mRNA expression of glucose
transporter 1 (GLUT-1) and lactate dehydrogenase (LDHA). For example, GLUT-1 expressed
on PANC-1 MCS was around 6.5 times higher than the corresponding monolayer cells and the
LDHA expression was 2.8 times higher (Longati et al., 2013). Another example, GLUT-1
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expression increased 2.6-3.4 times in HeLa MCS compared to the corresponding monolayer cells
(Rodríguez-Enríquez et al., 2008).
1.3.4. Acidic Microenvironment
In solid tumor, cancer cells generate excess amount of lactate (pKa=3.9) and hydrogen
ions (H+) as a result of glycolysis, which leads to a fall in intracellular pH (pHi). In order to
counter the acidic pHi, protons are exported across the plasma membrane by various transporters
such as H+-ATPase, Na+-H+ exchange, carbonic anhydrases and monocarboxylate transporter
(MCT), which maintains a favorable pHi of 7.0-7.2 but generates an acidic extracellular
microenvironment (Parks, Chiche, & Pouysségur, 2013; Swietach, Vaughan-Jones, & Harris,
2007). This acidic microenvironment in tumors has been verified in many studies. In one MCF7 breast cancer tumor, extracellular pH in the peripheral region of the tumor about 10 μm away
from capillary blood vessel wall is around 7.3, but drops to 6.7 in a region about 400 μm away
from the blood vessel wall (G. Helmlinger, Yuan, Dellian, & Jain, 1997). Acidification also
takes place inside MCS as a pH difference of 0.3–0.4 units is seen between the center (pH 6.9–
7.05) and the periphery (pH 7.3–7.4) in MCS of many cancer cell lines including HT29, V79379A, EMT6, U-138 MG, U-251 MG U-118 MG and HTh7 (Carlsson & Acker, 1988).
1.3.5. Cell-Cycle Arrest
Rapidly growing cancer cells experience hypoxia, nutrient deficiency and acidic
microenvironment, which induces necrotic cell death especially in the inner region of solid
tumors or spheroids. Many studies have demonstrated that MCS possesses a necrotic zone in the
center, a proliferating zone at the periphery and some quiescent cells in between, which cannot
be seen in monolayer cell cultures. MCS of various types of cancers, such as human breast
cancer, colon cancer and ovarian cancer is found to overexpress p27, a quiescence marker, by
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1.2~15 fold compared to the corresponding monolayer cells (Croix et al., 1996). In addition,
DLD-1 human colon adenocarcinoma MCS is found to express the proliferation marker Ki-67
mostly at the periphery, and yet the quiescence marker p27 at the center (Mellor, Ferguson, &
Callaghan, 2005).
1.3.6. Cellular Components
Besides carcinoma cells, solid tumors are heterogenic, and consist of many other types of
cells including immune cells (e.g., T lymphocytes, B lymphocytes, macrophages, NK cells and
lymphatic endothelial cell), tumor vascular endothelial cells, cancer-associated fibroblasts,
pericytes and adipocytes (Balkwill, Capasso, & Hagemann, 2012). Even though these cells are
non-malignant, they play important roles in tumor angiogenesis, progression, invasion,
metastasis and resistance by interacting with the surrounding cancer cells and with one another
(M. Wang et al., 2017). Cellular heterogeneity can also be achieved in MCS by co-culturing
stromal cells with cancer cells. For example, the coculture of colorectal tumor spheroids with
immune cells presented a relevant tool to study antitumor potential of immunomodulatory
antibodies (Courau et al., 2019); a triple co-culture of pancreatic cancer cells with fibroblasts and
endothelial cells closely mimicked the resistance to anticancer treatments (Lazzari et al., 2018).
1.3.7. Extracellular Matrix (ECM) Deposition
Extracellular matrix is a non-cellular matrix of biopolymers in all tissues. ECM is
composed of fibrous proteins (e.g., collagens, elastins, fibronectins, and laminins) and
proteoglycans (e.g., glycosaminoglycan). In normal tissues, ECM provides both structural and
biochemical support in regulating cell proliferation, cell adhesion and cell signaling (Frantz,
Stewart, & Weaver, 2010). In tumors, ECM protein dynamics become abnormal and the
deposition is elevated, such as increased collagen found in breast cancer (Levental et al., 2009;
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Provenzano et al., 2006). The ECM proteins are also found overexpressed in U-118 MG glioma
and HTh-7 thyroid spheroids (Nederman, Norling, Glimelius, Carlsson, & Brunk, 1984). ECM
proteins (e.g., proteoglycan and fibronectin) are expressed more in three dimensional spheroids
than in the corresponding monolayers (Glimelius, Norling, Nederman, & Carlsson, 1988).
1.3.8. Cell-ECM and Cell-Cell Physical Interactions
In a solid tumor, cell-ECM interactions (indicated by β1-integrin level) and cell-cell
interactions (indicated by E-cadherins level) are elevated compared to normal tissues. Such
elevation is associated with cancer cell signaling, proliferation, migration and invasion (Casey et
al., 2001; Walker, Mojares, & Del Río Hernández, 2018; Xiong & Xu, 2016). Cell-ECM and
cell-cell physical interactions are found to be more pronounced in MCS than the corresponding
monolayer cell cultures due to MCS’ spatial architecture. β1-integrins was significantly
increased in 3D epithelial ovarian cancer cell lines (OV-MZ-6 and SKOV-3) compared to 2D
(Loessner et al., 2010). E-cadherin was significantly higher in Huh7 spheroid compared to 2D
(Jung et al., 2017).
1.3.9. Physical Barrier
Elevated ECM protein deposition, cell-ECM interactions and cell-cell physical
interactions in solid tumors are also important concerns for anticancer drug development because
they increase tissue density and yield a physical barrier that limits the penetration of anticancer
drugs (Minchinton & Tannock, 2006).
1.4.

Lung Cancer

1.4.1. Lung Cancer and its Epidemiology
According to American Cancer Society, lung cancer is the second most common cancer
in both men and women (excluding skin cancer) and the leading cause of cancer death, making
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up nearly 25% of all cancers. It is estimated that in 2020, there will be about 228,820 new cases
of lung cancer and about 135,720 deaths from lung cancer (American Cancer Society, 2020).
1.4.2. Types of Lung Cancer
There are two types of lung cancers, small cell lung cancer (SCLC) and non-small cell
lung cancer (NSCLC), which need different treatment. About 15% of lung cancers are small cell
lung cancer (SCLC) and about 85% are non-small cell lung cancer (NSCLC). NSCLC has three
main subtypes: adenocarcinoma, squamous cell carcinoma and large cell carcinoma.
1.4.3. Staging
The progression of non-small cell lung cancer consists of 4 stages:
Stage I: Cancer is localized only in one lung and has not spread to any lymph nodes.
Stage II: Cancer is localized in lung and nearby lymph nodes.
Stage IIIA: Cancer has spread to lymph nodes but only on the same side of the chest where
cancer started growing.
Stage IIIB: Cancer has spread to lymph nodes on the opposite side of the chest, or above the
collar bone.
Stage IV: Cancer has spread to both lungs, or to fluid in the proximity, or to distant organs.
1.4.4. Treatment
Surgery, radiation, chemotherapy (chemo), targeted treatment and immunotherapy are
used to treat NSCLC, either alone or in combination. Surgery is mostly applied to stage I and
stage II patients to remove tumor. Radiation therapy is used alone or in combination with
chemo.
Chemotherapy can be given after surgery to kill remaining cancer cells, a strategy known
as adjuvant chemotherapy. Moreover, chemotherapy can be given before surgery to shrink the
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tumor size, a strategy known as neoadjuvant chemotherapy. In addition, chemotherapy is also
used to treat unresectable cancers. The commonly used chemo drugs include cisplatin,
carboplatin, vinorelbine, docetaxel, gemcitabine, etoposide and pemetrexed. Combination of
two chemo drugs are usually used, which often includes cisplatin or carboplatin plus one other
drug. Patients with certain gene mutations can be treated with targeted therapy drugs. For
example, Osimertinib, Afatinib, Erlotinib or Gefitinib is used for patients who are positive of
EGFR mutations, Alectinib or Brigatinib for ALK mutations, Crizotinib or Entrectinib for ROS1
mutations, and Dabrafenib plus Trametinib for BRAF mutations. Patients who have high level
of PD-L1 protein expression can be treated with immunotherapy, such as pembrolizumab.
1.5.

Hypothesis and Specific Aims

1.5.1. Statement of Purpose
Because of the afore-mentioned advantages of MCS to mimic many more features of
solid tumors than monolayer cell cultures, the purpose of this project is to characterize MCS of
lung cancer cells as an improved platform to evaluate drug candidates against lung cancer. Two
human lung cancer cell lines will be used, A549, which is one of the most investigated cell lines
of NSCLC, and A549-iRFP-Puro (A549-iRFP), which is derived from A549 and stably
expresses near-infrared fluorescent protein for convenient detection.
1.5.2. Hypothesis
This project aims to test the hypothesis that the sensitivity of MCS A549 and A549-iRFP
to anticancer drugs better reflect the drugs’ efficacy against lung cancer in clinic than the
corresponding monolayer cells.
1.5.3. Specific Aims
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This project has the following three specific aims. Aim 1, to construct A549 MCS and
A549-iRFP MCS; Aim 2, to compare the sensitivity of A549 and A549-iRFP MCS to several
well-established chemotherapy drugs with the sensitivity of the corresponding A549 and A549iRFP monolayers; Aim 3, to evaluate the viability of the fluorescent A549-iRFP MCS after
treatment with the anti-lung cancer drugs based on their clinical regimens.
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CHAPTER 2: CONSTRUCTION OF MCS OF A549 AND A549-iRFP
2.1.

Introduction

2.1.1. A549 and A549-iRFP Cells
A549 is adenocarcinoma human epithelial cells, developed from the lung of a 58-year old
male Caucasian. It has been used as a model of NSCLC in many studies, from basic mechanism
of lung cancer to novel drug development (Liebmann et al., 1993). A549-iRFP-Puro is a
polyclonal population of the human lung carcinoma cell line A549 (ATCC® CCL-185™) that
stably express near-infrared fluorescent protein (iRFP) and can be selected using puromycin.
The fluorescence ex/em is 690/713 nm which makes in vivo and ex vivo imaging of implanted
cells easier, since biological tissues have lower absorption and less autofluorescence at 600 to
1000 nm (Hilderbrand & Weissleder, 2010).
2.1.2. Methods for MCS Formation
In recent years, various methods have been developed for the formation of MCS. It is
important to fabricate multicellular spheroids with controllable and uniform size, biological
functions and 3D microenvironment that best mimics tumors in vivo. Conventional and
commonly used methods can be divided into scaffold-based and scaffold-free methods.
In a scaffold-based method, as its name suggests, scaffold is applied to help form MCS
that provides not only the 3D structure but also cell-cell and cell-matrix interactions. Hydrogels
are widely used as scaffold, which includes natural hydrogel (e.g., collagen, Matrigel™ and
hyaluronic acid-based hydrogels) and synthetic hydrogel (e.g., Poly(ethylene glycol) (PEG),
Poly(N-isopropylacrylamide) (PNIPAM) and Poly(Ꜫ-carpolacton) (PCL)) (Cui, Hartanto, &
Zhang, 2017). There are two types of scaffold-based methods: matrix-based method and
microfabrication method. A typical type of scaffold-based methods is matrix-based method, in
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which MCS could be either formed on top of the matrix or inside the matrix. A more complex
scaffold-based method is the microfabrication method, it involves hydrogel and needs to use
specially made equipment such as micropatterned plates or microfluidic platforms.
In a scaffold-free method, spinner flasks, NASA rotating flasks and pellet culture method
involves agitation, while other methods such as hanging drop, ultra-low cell attachment plate
method, liquid overlay and magnetic levitation and 3D bioprinting are agitation-free.
Descriptions and comparisons of the above-mentioned methods are listed in Table 1. Even
though each method has significant limitations, they could be combined to complement one
another and thus produce better MCS.
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Table 1
Comparison of Common 3D MCS Formation Methods
Methods
S
c
a
f
f
o
l
d
b
a
s
e
d

M
atr
ix

Mi
cr
of
ab
ric
ati
on

A
git
ati
on
ba
se
d
S
c
a
f
f
o
l
d
f
r
e
e

A
git
ati
on
fre
e

Advantage

Disadvantage

Cells are either seeded on top
of a solidified layer of matrix
or seeded along with liquid
matrix

Provide 3D
support that
mimics in vivo

Variable sizes;
Spheroids
overlapping with
each other;
difficult to
retrieve cells

Micro
pattern
ed
plates

Cells are aggregate in a
hydrogel-coated microwells
plate

Controllable and
uniform size;
Suitable for HTS

Need to prepare
micropatterned
chamber

Microf
luidic
platfor
ms

Cells aggregate and grow in a
hydrogel-coated or filled
microchannels in a perfusion
system

Long term culture;
Provide dynamic
3D
microenvironment

Spinne
r
flasks
NASA
Rotati
ng
flasks

Cells aggregate by preventing
their adhesion on material
surface via constant stirring
Cells aggregate by preventing
their adhesion on material
surface via constant rotating in
a microgravity environment

Difficult to
harvest;
Specialized
equipment
required; Not
suitable for HTS

Simple to perform;
Long term culture;
Mass production

Variable sizes
and
morphologies
due to shear
stress; Not for
large scale

Pellet
culture

Cells aggregate by
centrifugation

Simple to perform;
Rapid formation

Hangi
ng
drop

Cells aggregate spontaneously
in the bottom of a droplet of
culture medium relying on
gravity

Low cost; Uniform
size and shape;
Simple to perform;
Rapid formation

Ultralow
cell
attach
ment
plates

Cells aggregate by culturing
them on a hydrophilic,
neutrally charged coating

Easy to image;
Easy to change
media; Easy to
harvest; Long term
culture; Suitable
for HTS

Liquid
Overla
y

Cells aggregate by culturing
them on a concave nonadherent substrate

Magne
tic
levitati
on

Magnetically labeled cells
(incubated with magnetic
nanoparticles) are pulled up
under magnetic forces where
magnet is placed on top of the
plate

Matrix
on-top
and
matrix
embed
ded

Description

Cells may be
damaged by
shear stress
Fragile; Hard to
change media;
Low throughput;
Limited culture
period

Reference
(IngesonCarlsson,
MartinezMonleon, &
Nilsson, 2015;
Lee, Kenny, Lee,
& Bissell, 2007)
(MarkovitzBishitz et al.,
2010; Sunami,
Yokota, &
Igarashi, 2014)
(Lim & Park,
2018; Wu et al.,
2011)
(Lazar et al.,
1995)
(Ingram et al.,
1997)
(Li, He, & Pei,
2011)
(Tung et al.,
2011)

Expensive

(Vinci et al.,
2012)

Low cost; Simple
to perform

Variable sizes
size and
morphologies;
Hard to harvest;
Low throughput

(Costa, de MeloDiogo, Moreira,
Carvalho, &
Correia, 2018)

Rapid formation

Not for large
scale; Cells need
to be pretreated
with magnetic
nanoparticles

(Haisler et al.,
2013)
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(Table 1 Continued)
Magne
tic 3D
biopri
nting

Magnetically labeled cells
(incubated with magnetic
nanoparticles) are pulled down
under magnetic forces where
magnet is placed beneath the
plate

(Tseng et al.,
2015)
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2.1.3. Characterization and Evaluation of MCS
Many assays have been used to evaluate MCS growth and its response to growth factors
and drug treatments (listed in Table 2). Methods usually used on monolayer can also be used on
MCS. However, although MTT assay has been used on MCS, it is not highly recommended
since it is harder to penetrate MCS. Instead, CellTiter-Glo® can be a substitute assay to quantify
MCS viability (Riss, 2017).
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Table 2
Comparison of Assay Methods Used in MCS
Cellular
activity

Apoptosis
assay/ cell
death
analysis

Cytotoxicit
y assay

Cell
proliferatio
n and cell
cycle assay

Assay

Assay
example

DNA
fragmentation

TUNEL assay

Caspase activity

Caspase
assays

Phosphatidylseri
ne exposure
Released
intracellular
protein
Damage of cell
membrane
Vital dyes
Combined dye

ATP

Cell
viability
assay

Morphologi
cal changes

Tetrazolium

Reference
(Gunther, Pawlak, Damasceno, Arnold, & Terzis, 2003;
Gabriel Helmlinger, Netti, Lichtenbeld, Melder, & Jain,
1997)
(Kessel et al., 2017)

Annexin V

(Andrea & Manfred, 2006; Yamaguchi et al., 2010)

G6PD

(W. Wang et al., 2018)

LDH assay

(Xu, Ma, & Purcell, 2003)

7-AAD

(Patra, Peng, Liao, Lee, & Tung, 2016)

Calcein-AM
Trypan blue
Propidium
iodide
Live/dead cell
viability assay

(Patra et al., 2016)
(Ivanov et al., 2014)

CellTiterGlo®

ViaLight™
plus kit
MTT assay
MTS assay

(Andrea & Manfred, 2006)
(Sirenko et al., 2015)

(Kessel et al., 2017; Vinci et al., 2012)

(Nie, Garner, & D'Souza, 2017)
(Ho, Yeap, Ho, Rahim, & Alitheen, 2012)
(Yeon et al., 2013)

Resazurin

Alamar blue
assay

(Ivanov et al., 2014)

Acid Phosphatase

APH assay

(Ivanov et al., 2014)

Morphology,
diameter and
volume

Inverted
microscope

(Vinci et al., 2012)

2.2.

Materials and Methods
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2.2.1. Materials
A549 cell line was purchased from ATCC (VA, US). A549-iRFP cell line was purchased
from Imanis Life Sciences (MN, US). RPMI 1640, DMEM, Collagen, Trypsin-EDTA, 1%
penicillin-streptomycin and Live/DEADTM Cell Imaging Kit were purchased from ThermoFisher. Puromycin was purchased from Alfa Aesar (MA, US). Fetal bovine serum was
purchased from Gemini Bio-Products (CA, US). Ultra Cruz® Black/Clear Flat bottom 96-well
microplates were purchased from Santa Cruz (CA, US). White Flat Bottom 96-well microplates
and 96-well Spheroid microplates were purchased from Corning Life Science (NY, US).
CellTiter 96® AQueous One Solution Cell Proliferation Assay and CellTiter-Glo® 3D Cell
Viability Assay kits were purchased from Promega Corporation (Madison, WI, US). Cisplatin,
Doxorubicin Hydrochloride was purchased from BIOTANG Inc. (MA, US). Carboplatin was
purchased from ChemScene llc (NJ, US). Paclitaxel and Gemcitabine Hydrochloride were
purchased from LC Laboratory (MA, US)
2.2.2. Cell Culture Maintenance
A549 cells were maintained in RPMI 1640 supplemented with 10% fetal bovine serum
(Gemini, CA, US) and 1% Penicillin-Streptomycin (Corning Life Science, NY, US). A549-iRFP
cells were maintained in DMEM supplemented with 10% fetal bovine serum (Gemini, CA, US),
1% Penicillin-Streptomycin (Corning Life Science, NY, US), and 1 μg/ml puromycin (Alfa
Aesar, MA, US). Cells were grown in 5% CO2 at 37 °C and passaged at 85% confluence (3~4
days).
2.2.3. Formation of 3D MCS
NSCLC cell lines A549 and A549-iRFP were seeded at 5000 cells in 100 µl growth
media for each well with 0.3% collagen onto Corning 96-well spheroid microplates (Corning
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Life Science, US), which were then centrifuged at 300 × g for 7 min by Eppendorf Centrifuge
5810R. Plates were incubated for 48 hours then supplemented with another 100 µl growth
media. Media was changed every other day by replacing 100 µl media in microplates with 100
µl fresh media to ensure a total volume of 200 µl. The growth and morphology of MCS were
observed by Keyence (US) BZ-X700 fluorescence microscope.
2.2.4. Characterization and Optimization of 3D MCS Viability Assay
A549-iRFP cells were seeded at 3000 cells/well in 96-well spheroid microplates to form
A549-iRFP MCS as described above. Certain amount MCS were collected each time for
experiment when diameter reaching around 350 µm, 550 µm, 750 µm, and 950 µm. MCS were
divided into 6 groups, according to the volume ratio between MCS with media and CellTiterGlo® 3D Cell Viability Assay varying from 1:1 to 1:6. The total working volume was 200μl for
each well. Each group had 2 subgroups of a 5-minute shaking time as described in 3D cell
viability assay’s protocol and another group of 10 minutes shaking time (see Table 1). Assay
was used as protocol except 5 more additional ratios of sample volume to reagent volume were
added from 1:2 up to 1:6, and another set of groups was vigorously shaking for additional 5
minutes other than the protocol. In general, MCS were collected and transferred to opaquewelled plates, assay was added to each well as calculated (see Table 1). Microplates were
vigorously mixed as its designated time group and incubated at room temperature for additional
25 minutes. The luminescence was then recorded by a Synergy HTX microplate reader (BioTek,
US). Samples were evaluated in at least replicates.
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Table 3
3D Assay Validation Detail
𝑉𝑉𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠 (𝜇𝜇𝜇𝜇)
𝑉𝑉𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑦𝑦 (𝜇𝜇𝜇𝜇)
1:1
1:2
1:3
1:4
1:5
1:6

5 min

10 min

Vsample(μl)

Vassay(μl)

Vsample(μl)

Vassay(μl)

100.0
66.7
50.0
40.0
33.3
28.6

100.0
133.3
150.0
160.0
166.7
171.4

100.0
66.7
50.0
40.0
33.3
28.6

100.0
133.3
150.0
160.0
166.7
171.4

2.2.5. Imaging of Live/Dead in A549 3D MCS
A549 cells were seeded at 5000 cells/well in 96-well spheroid microplates to form A549
3D MCS as described above. A549 MCS were transferred to a glass Petri dish when the
diameter reached 500 µm and incubated with Live/DEADTM Cell Imaging Kit at room
temperature for 45 minutes before washed 3 times with PBS buffer. A549 3D MCS were
imaged by a Leica DMIRE2 confocal microscope. Excitations at 491nm and 561nm were used
for live and dead dyes, respectively,; since the live dye can produce an intensive green
fluorescence in live cells at ex/em ~494 nm/~517 nm, and dead dye gives a bright red
fluorescence at ex/em ~528 nm/~617 nm. Images were acquired with MetaMorph and analyzed
by using ImageJ software.
2.2.6. Data Analysis.
Data are presented as mean ± standard deviation (SD) for assay characterization study.
The statistical analysis is performed by two-way analysis of variance (ANOVA) for assay
characterization study using GraphPad Prism 8.0 Software (GraphPad Software, La Jolla, CA).
Tukey’s multiple comparisons test analysis was performed to compare between groups. Results
with p < 0.05 were accepted as statistically significant.
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2.3.

Results and Discussion

2.3.1. Formation of 3D A549 and A549-iRFP MCS
Among methods described above, matrix, centrifugation and ultra-low attachment plate
methods are used together in our lab to form spheroids. Controllable and uniform size MCS
were formed in both A549 and A549-iRFP with the use of 0.3% collagen and centrifugation at
300 × g. As is shown in Figure 2, MCS were tight and relatively round shape, and the size of
MCS grew bigger over time in both cell lines. Growth curves were also validated in volume and
cellular viability, both of which increased over days (Figure 3).

Figure 2. Morphology of MCS on day 1, 3, 5, 7, 9 and 11. Tight and relatively round shape 3D
MCS were formed. Size of MCS grew bigger over days (represented by diameter). (A) 3D A549
MCS; (B) A549-iRFP MCS; cells were seeded 5000 cells/well.

33

Figure 3. Growth curves of A549 and A549-iRFP MCS. Size of MCS (represented by volume)
grew bigger over days so as viable cells (represented by cellular ATP, measured by 3D MCS
viability assay). (A, B) 3D A549 MCS; (C, D) A549-iRFP MCS; same group of MCS as is used
in Figure 2.
2.3.2. Characterization and Optimization of 3D Cell Viability Assay Condition
According to the 3D cell viability assay’s protocol, a volume of reagent equal to cell
culture media present in each well should be added, and then vigorously mix for 5 minutes to
induce cell lysis. Plate is incubated for 25 minutes to stabilize the luminescent signal before
reading. However, considering MCS will probably grow very big at the end of our studies, 1:1
ratio of MCS to reagent volume and 5 minutes mixing time may not be enough mixing.
Insufficient mixing will result in inaccurate readouts, because less ATP will be released and
result in underestimated luminescent signal level. Therefore, in order to produce effective ATP
extraction from MCS so that optimum assay performance can be achieved, higher ratios of
reagent volume were added and longer mixing time was also being tested. Among all the size
ranges, there are no significant differences between 1:1 and each tested ratio (1:2, 1:3, …, 1:6),
and no difference is seen between 5 minutes and 10 minutes mixing time (results shown in
Figure 4), which means the amount of reagent used and time for mixing in protocol are enough
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to lyse cells and can react thoroughly. Therefore, 3D viability assay can be carried out as
specified in the protocol’s steps, no adjustment needed to be done.

Figure 4. 3D cell viability assay validated on different sizes of 3D A549-iRFP spheroids. There
is no significant difference among different volume ratio between sample and assay in all sizes
and shaking time being tested, and no significant difference under 5 minutes and 10 minutes
shaking time in all sizes and ratio. (P>0.05 for two-way ANOVA). (A) 3D A549-iRFP spheroids
at diameter ~350μm; (B) 3D A549-iRFP spheroids at diameter ~550μm; (C) 3D A549-iRFP
spheroids at diameter ~750μm; (D) 3D A549-iRFP spheroids at diameter ~950μm.
2.3.3. Distribution of Live and Dead Cells in 3D A549 MCS
Figure 5A shows a cross section of a 3D MCS A549 that is 500 µm in diameter by
confocal microscope, taken 200 µm from the bottom which is close to the core. The green
fluorescence is from fluorescent calcein representing live cells, red fluorescent comes from
EthD-1 which represents dead cells. From both confocal image (Figure 5A) and relative
fluorescent intensity (Figure 5B), green signals can be seen more in peripheral area while red
signals are more centered in the core. This means live cells are located at outside layer while
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dead cells are more accumulated in core area, which confirms that necrotic core is formed in 3D
A549-iRFP at the size of 500 µm.
This phenomenon can also be seen in 3D MCS A549-iRFP done by our lab previously,
shown in Figure 6 (Yingbo, 2019). The diameter of chosen MCS was also around 500 µm, and
the cross section was also taken 200 µm from the bottom, using same experimental conditions.
The distribution of green and red fluorescence signal in MCS shown in Figure 6 confirms the
existence of necrotic core in 3D MCS of A549-iRFP.

Figure 5. Confocal image of live/dead cells in A549 3D MCS. (A) Confocal image shows the
distribution of live and dead cells in A549 3D MCS; (B) Relative fluorescent intensity profile
indicates the distribution of live cells and dead cells vary in 3D A549 MCS; green fluorescent
represents live cells; red fluoresce represents dead cells.
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Figure 6. Confocal image of live/dead cells in A549-iRFP 3D MCS. (A) red fluorescent signal
(B) green fluorescent signal (C) merged image of two signals (D) image of 3D A549-iRFP MCS
taken in brightfield.
2.4.

Summary

Round, tight and uniform MCS of both A549 and A549-iRFP are successfully
constructed at selected seeding density on ultra-low attachment plates using collagen and
centrifugation. Their sizes are controllable and grows bigger over days. Necrotic cores are
located at the center of MCS on both cell lines when sizes reach 500 µm. CellTiter-Glo®, a 3D
cell viability assay, can be used to evaluate MCS viability after drug treatment under specified
protocol procedures even when diameter is larger than 1000 µm.
Of interest is that these MCS only consist of carcinoma cells, which does not have other
type of cells that a solid tumor has, for example fibroblasts and endothelial cells. Those
components are important in mimicking solid tumor heterogenic cellular constitution which
further support cell-cell and cell-matrix interactions. However, because of the collagen we used,
it provided the matrix for cells to grow and aggregate, leading to cells diversifying into
proliferating cells, quiescent cells and non-proliferating cells. Even though there is only one type
of cell, we still developed MCS that mimics solid tumor better than monolayer cells.
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In this way, our lab combined three methods to form A549 and A549-iRFP MCS
successfully which are ready to be used in drug screening. This method is quite novel and has
high success rate of providing good spheroids in large amount, especially ideal for HTS.
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CHAPTER 3: RESPONSE OF MCS TO ANTICANCER DRUGS COMPARED TO
MONOLAYERS

3.1.

Introduction

After the successful construction of A549 and A549-iRFP MCS, four anticancer drugs,
namely cisplatin, carboplatin, gemcitabine and doxorubicin were chosen to be assessed on their
ability to inhibit the growth of MCS. These four anticancer drugs were chosen because they are
widely used in A549 related studies, cisplatin and carboplatin are drugs of choice in clinical
settings (Edelman, Quam, & Mullins, 2001; Punia, Raina, Agarwal, & Singh, 2017; Shali et al.,
2018; Teng et al., 2018; Varbanov, Kuttler, Banfi, Turcatti, & Dyson, 2019). Gemcitabine is
more frequently used in squamous cell NSCLC while doxorubicin is indicated in small-cell lung
cancer. These two drugs are used as negative controls. Four types of cell culture were used:
A549 monolayer cells, A549 MCS, A549-iRFP monolayer cells, and A549-iRFP MCS due to the
afore-mentioned advantages of MCS to mimic more features of solid tumors than monolayer cell
cultures (Chapter I).
3.1.1. Cisplatin
Cisplatin is the first platinum-based anticancer agent. It was approved by FDA in 1978.
It exhibits broad spectrum of antitumor activity in various cancer types including testicular,
ovarian, lung, head and neck, and bladder cancers. It has several side effects, for example,
serious emesis, neurotoxicity, and nephrotoxicity (which is often dose-limiting toxicity). The
mechanism of action is due to its interaction with DNA. The chloride ligands of cisplatin are
replaced by H2O molecules once inside cells, then covalently bind to the N7 site of purine base
of DNA to form intrastrand crosslinks. This cisplatin-DNA adducts distort the DNA duplex
structure which block DNA replication and transcription (D. Wang & Lippard, 2005).
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3.1.2. Carboplatin
Carboplatin is the second FDA-approved antitumor agent from the Platinum drug family.
It has a similar antitumor spectrum to cisplatin, and has cross-resistance with cisplatin.
Carboplatin is generally more tolerable than cisplatin, and its dose limiting toxicity is
myelosuppression. Carboplatin’s mechanism of action is similar to cisplatin, however,
cyclobutane-1,1-dicarboxylate in carboplatin makes it more resistant to aquation and therefore
slower to form carboplatin-DNA adducts (Knox, Friedlos, Lydall, & Roberts, 1986).
3.1.3. Doxorubicin
Doxorubicin is an anthracyline anticancer drug. It was first extracted from Streptomyces
peucetius var. caesius (Arcamone et al., 1969). It is used for the treatment of variety of cancers,
such as breast cancer, small-cell lung cancer, ovarian cancer, acute lymphoblastic leukemia,
Hodgkin lymphoma, etc. There are two main mechanisms of its cytotoxicity, intercalation into
DNA and generation of free radicals. The first mechanism inhibits the DNA synthesis while the
second leads to DNA and cell membrane damage (Thorn et al., 2011).
3.1.4. Gemcitabine
Gemcitabine is a nucleoside analog of deoxycytidine that exhibits anticancer activity in
breast cancer, non-small cell lung cancer and bladder cancer. Gemcitabine is cell phase specific,
which kills cells during DNA synthesis (S-phase). It is metabolized intracellularly into
diphosphate (dFdCDP) and triphosphate (dFdCTP) nucleosides, both of which attribute to
inhibition of DNA synthesis (Eli Lilly, 1996).
3.2.
3.2.1. Materials

Materials and Methods
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A549 cell line was purchased from ATCC (VA, US). A549-iRFP cell line was purchased
from Imanis Life Sciences (MN, US). RPMI 1640, DMEM, Collagen, Trypsin-EDTA, and 1%
penicillin-streptomycin were purchased from Thermo-Fisher. Puromycin was purchased from
Alfa Aesar (MA, US). Fetal bovine serum was purchased from Gemini Bio-Products (CA, US).
Ultra Cruz® Black/Clear Flat bottom 96-well microplates were purchased from Santa Cruz (CA,
US). White Flat Bottom 96-well microplates and 96-well Spheroid microplates were purchased
from Corning Life Science (NY, US). CellTiter 96® AQueous One Solution Cell Proliferation
Assay and CellTiter-Glo® 3D Cell Viability Assay kits were purchased from Promega
Corporation (Madison, WI, US). Cisplatin and Doxorubicin Hydrochloride were purchased from
BIOTANG Inc. (MA, US). Carboplatin was purchased from ChemScene llc (NJ, US).
Gemcitabine Hydrochloride was purchased from LC Laboratory (MA, US)
3.2.2. Cell Culture Maintenance
A549 cells were maintained in RPMI 1640 supplemented with 10% fetal bovine serum
(Gemini, CA, US) and 1% Penicillin-Streptomycin (Corning Life Science, NY, US). A549-iRFP
cells were maintained in DMEM supplemented with 10% fetal bovine serum (Gemini, CA, US),
1% Penicillin-Streptomycin (Corning Life Science, NY, US), and 1 μg/ml puromycin (Alfa
Aesar, MA, US). Cells were grown in 5% CO2 at 37 °C and passaged at 85% confluence (3~4
days).
3.2.2.1.

Cytotoxicity Assay for Selected Anticancer Drugs on 2D Monolayer Cells.

A549 and A549-iRFP cells were seeded onto Ultra Cruz® Clear and Black flat-bottom 96-well
microplates (Santa Cruz, CA, US), respectively, at seeding density of 5000 cells/well. Cells
were grown overnight to be prepared for the cytotoxicity assay. The growth media was then
replaced by media containing the drug at decremental concentrations, for which each selected
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drug was dissolved in water and diluted with media by 10 fold to prepare the highest
concentration of the drug solution in media, followed by further dilution with media to
decremental concentrations. Drug solutions in media were replaced by growth media after 72
hours and/or 48 hours incubation. Reagent solution (20 µl/well) of the CellTiter 96® AQueous
One Solution Cell Proliferation Assay was then added and incubated for 3 hours, after which UV
absorbance (λ=490 nm) was read by a Synergy HT microplate reader. One set of cells were
treated with drug-free growth media for each experiment and assayed in parallel as control,
whose viability was taken as 100%. Wells in microplates with no seeded cells were also assayed
in parallel as the blank. Viability for each assay sample at various drug concentrations were
calculated as the following equation (Equation 3.1):

𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉(%) =

(Ax -Ablank )
× 100%
(Acontrol -Ablank )

Equation 3.1

Samples were evaluated in triplicates or more.
3.2.2.2.

Cytotoxicity Assay for Selected Anticancer Drugs in 3D MCS Cell Model.

A549 and A549-iRFP cells were seeded 5000 cells/well onto Corning 96-well spheroid
microplates (Corning Life Science, NY, US) to form MCS as described previously (Chapter
section 2.2.3). Spheroids were grown to diameter ~ 500 μm in 5 to 6 days after seeding to be
prepared for the assay. Media was then replaced by drug solutions in media at decremental
concentrations, for which the drug (except cisplatin) was dissolved in water and diluted by 10
fold with media to prepare the highest concentration, followed by further dilution with media to
decremental concentrations. Because of its poor solubility in water, cisplatin was directly
dissolved in media and then further diluted with media to decremental concentrations. Drug
solutions in media were replaced by 100 µl growth media after 48-72 hours incubation with
cells. Reagent solution (100 µl) of CellTiter-Glo® 3D Cell Viability Assay was added to each
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well, and the plates were shaken for 5 min and then incubated for 25 min, after which
luminescence was recorded by a Synergy HT microplate reader. One set of cells were treated
with drug-free growth media for each experiment and assayed in parallel as control, whose
viability was taken as 100%. Viability for each sample at various drug concentrations were
calculated by the following equation (Equation 3.2):
𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉𝑉(%) =

Ax

Acontrol

Equation 3.2

× 100%

Samples were evaluated in triplicates or more.
3.2.3. Data Analysis
Data are presented as mean ± standard deviation (SD) for all cytotoxicity assay studies.
IC50 values were estimated by nonlinear regression [log(inhibitor) vs. response, Variable slope,
four parameters] using GraphPad Prism 8.0 Software (GraphPad Software, La Jolla, CA). The
statistical analysis is performed by unpaired t test to compare statistical difference of IC50
between monolayer and MCS using GraphPad Prism 8.0 Software (GraphPad Software, La Jolla,
CA). Results with P < 0.05 were accepted as statistically significant.
3.3.

Results

3.3.1. Sensitivity of A549 Monolayer Cells and MCS to Anticancer Drugs
A549 cells, either in monolayer or in MCS, were treated with different anticancer drugs
at decremental concentrations and their viability is presented as dose-response curves in Figure
7. Concentration of different anticancer drugs that is required to inhibit fifty percent growth
(IC50) of A549 monolayer cells and MCS were then estimated from data in Figure 7 using the
GraphPad Prism software and are shown in Table 4. The four selected chemotherapy drugs were
firstly tested in 2D monolayer cells. Three of the drugs, namely cisplatin, carboplatin and
doxorubicin inhibited most viability of the monolayer cells below 200 μM except for
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gemcitabine. The four drugs were then evaluated in 3D MCS cell culture. Except for
gemcitabine, which was not active at the highest dose tested, the drugs generated typical doseresponse curves in 3D MCS. IC50 values in MCS was estimated with high reproducibility.
Therefore, the 3D MCS viability assay can be readily used to reliably evaluate drug activity.
Moreover, table 4 compares IC50 values between A549 monolayer cells and A549 MCS, which
reveals higher IC50 values in MCS (e.g., 10-fold higher IC50 of doxorubicin for A549 MCS than
A549 monolayer cells).
MCS have properties that are similar to that of solid tumor, which monolayer cells don’t
have, such as hypoxic and acidic microenvironment, increased cell-cell and cell-matrix
interactions and cellular heterogeneity. Those properties may lead to inability of compounds to
penetrate through cells or to alter cell signaling, which in turn induces drug resistance in 3D
MCS. However, the literature has also reported cases of increased drug sensitivity in 3D MCS
over monolayer cells. Trastuzumab, a targeted anticancer drug, can reduce 48% of SKBR-3 3D
MCS growth but only 16% of the corresponding monolayer cells at the same concentration. The
authors of this investigation concluded it was because the 3D MCS was more representative of
the HER2 signaling pathway in tumors in vivo (Pickl & Ries, 2009). Still, another example is
that 2D A431.H9 cells maintained 72% viability after treatment with tirapazamine (TPZ), while
the corresponding 3D MCS maintained only 40% viability. This higher sensitivity of 3D MCS
to the drug was explained by the need of TPZ to be activated by hypoxia, which was prominent
in 3D MCS but not in 2D monolayer cells (Tung et al., 2011). These two examples highlight the
fact that MCS do not necessarily induce drug resistance, but the combination of the drug and the
three dimensional cellular environment in MCS can substantially alter the drug effect and
probably better reflect the drug’s effect in vivo.
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Figure 7. Representative dose-dependant viability curves of A549 monolayer cells (blue) and
MCS (red) after exposure to anticancer drugs. (A) cisplatin, (B) carboplatin, (C) doxorubicin,
and (D) gemcitabine. Data presented as mean ± SD, N ≥3.
Table 4
IC50 Values of Different Anticancer Drug on A549 Monolayer Cells and MCS. Data Presented
as Mean ± SD Of Three Separate Experiments. (P>0.05 for Unpaired T Test).
P value between
𝐼𝐼𝐼𝐼50(3𝐷𝐷)
2D (μM)
3D (μM)
(𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓) IC50 on 2D and 3D
𝐼𝐼𝐼𝐼50(2𝐷𝐷)
0.0040
cisplatin
9.07 ± 3.27
20.71 ± 2.63
2.28
0.0100
carboplatin 131.80 ± 10.66 188.90 ± 18.68 1.43
0.0302
doxorubicin 0.63 ± 0.23
6.57 ± 2.88
10.37
N/A
gemcitabine >100
>100
N/A

3.3.2. Sensitivity of A549 Monolayer Cells and MCS to Anticancer Drugs
A549-iRFP cells, either in monolayer or in MCS, were treated with different anticancer
drugs at decremental concentrations and their viability is presented as dose-response curves in
Figure 8. IC50 of different anticancer drugs on A549-iRFP MCS and monolayer cells were
estimated from data shown in Figure 8 using the GraphPad Prism software. The resultant IC50
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values are shown in Table 5. The four anticancer drugs showed similar results in A549-iRFP
cells compared to A549. Specifically, gemcitabine is still not active at the highest dose tested
while dose-response curves are prominent for cisplatin, carboplatin, and doxorubicin in both 2D
and 3D cultures. Similar to the data for A549 cells (Table 4), the IC50 value of cisplatin,
carboplatin, and doxorubicin against A549-iRFP 3D MCS was substantially higher than that
against A549-iRFP monolayer cells (Table 5). However, as is shown in Table 6, parts of the
IC50 values of A549-iRFP for both the 2D monolayer cells and the 3D MCS are comparable to
those in A549 (P > 0.05 for unpaired t test), but some are statistically different (P < 0.05 for
unpaired t test). A549-iRFP is parental A549 cells transduced with LV-iRFP-P2A-Puro
(LV032), so it does not necessarily exhibit exact same drug response as A549, there are still
some limitations of using A549-iRFP to represent A549. But in general, A549-iRFP shows same
trend as A549 that 3D MCS needs higher concentration to inhibit 50% of cell growth than the
corresponding 2D monolayer cells.
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Figure 8. Representative dose-dependant viability curves of A549-iRFP monolayer cells (blue)
and MCS (red) after exposure to anticancer drugs. (A) cisplatin, (B) carboplatin, (C)
doxorubicin, and (D) gemcitabine. Data presented as mean ± SD, N ≥3.
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Table 5
IC50 Values of Different Anticancer Drugs on A549-iRFP Monolayer Cells and MCS. Data
Presented as Mean ± SD of Three Separate Experiments. (P>0.05 for Unpaired T Test).
𝐼𝐼𝐼𝐼50(3𝐷𝐷)
P value between
2D (μM)
3D (μM)
(𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓)
IC50 on 2D and 3D
𝐼𝐼𝐼𝐼50(2𝐷𝐷)
cisplatin
carboplatin
doxorubicin
gemcitabine

12.25 ± 1.04
197.24 ± 33.61
0.9 ± 0.45
>100

50.67 ± 15.29
265.63 ± 23.31
4.18 ± 0.76
>100

4.14
1.35
4.65
N/A

0.0010
0.0221
0.0008
N/A

Table 6
Comparison of IC50 Between A549 and A549-iRFP of Different Drugs on Their Corresponding
Culture Type. (P>0.05 for Unpaired T Test).
P value between
P value
𝐼𝐼𝐼𝐼
𝐼𝐼𝐼𝐼50(3𝐷𝐷, 𝐴𝐴549−𝑖𝑖𝑅𝑅𝑅𝑅𝑅𝑅)
50（3𝐷𝐷, 𝐴𝐴549−𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖)
A549 and
between A549
(𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓)
(𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓)
𝐼𝐼𝐼𝐼50(3𝐷𝐷, 𝐴𝐴549)
𝐼𝐼𝐼𝐼50(2𝐷𝐷, 𝐴𝐴549)
A549-iRFP on
and A549-iRFP
2D
on 3D
cisplatin
P>0.05
1.35
0.0233
2.45
carboplatin 0.0297
1.50
0.0112
1.41
doxorubicin P>0.05
1.42
P>0.05
0.64
3.4.

Summary

Drug response curves of cisplatin, carboplatin and doxorubicin were successfully
generated in MCS of both A549 and A549-iRFP cell lines. The 3D cytotoxicity protocol
described in this chapter can be used to evaluate compounds as potential anti- lung cancer drugs
because it is reproducible and easy to operate. Higher concentration of the tested anticancer
drugs are needed to inhibit 50% the cell viability in MCS than monolayer A549 and A549-iRFP
cells, which can be explained by the MCS properties that are absent in monolayer cells (Chapter
I), such as hypoxic and acidic microenvironment, cellular heterogeneity and increased cell-cell
and cell-matrix interactions.
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CHAPTER 4: TREATING MCS OF LUNG CANCER CELLS WITH CHEMOTHERAPY
AGENTS BASED ON CLINICAL REGIMENS
4.1.

Introduction

4.1.1. Clinical Regimens
Cisplatin, carboplatin, vinorelbine, docetaxel, etoposide, gemcitabine, pemetrexed and
paclitaxel are commonly used chemotherapy drugs against NSCLC. These drugs are usually
used in combinations in clinical regimens to treat NSCLC. Table 7 lists preferred chemotherapy
regimens for NSCLC neoadjuvant and adjuvant therapy based on National Comprehensive
Cancer Network® (NCCN®) Guidelines on non-small cell lung cancer (Version 3.2020)
(NCCN, 2020).
Table 7
NCCN Guidelines® NSCLC Chemotherapy Regimens for Neoadjuvant and Adjuvant Therapy

cisplatin

75 mg/m2

day 1

+

pemetrexed

500 mg/m2

day 1 every 21 days for 4 cycles

cisplatin

75 mg/m

2

day 1

+

gemcitabine

days 1 and 8, every 21 days for 4 cycles

cisplatin

75 mg/m2

day 1

+

docetaxel

1250
mg/m2
75 mg/m2

cisplatin

50 mg/m

days 1 and 8

+

vinorelbine

25 mg/m

cisplatin

100 mg/m2

day 1

+

vinorelbine

30 mg/m2

cisplatin

75-80
mg/m2
100 mg/m2

day 1

+

vinorelbine

day 1

+

etoposide

25-30
mg/m2
100 mg/m2

days 1, 8, 15, and 22, every 28 day for 4
cycles
days 1, 8, 15, and 22, every 28 day for 4
cycles
days 1 and 8, every 21 days for 4 cycles

cisplatin

2

day 1 every 21 days for 4 cycles

2

days 1-3 every 28 day for 4 cycles

Chemotherapy Regimens for Patients with Comorbidities or Patients Not Able to Tolerate Cisplatin
carboplatin AUC 6
day 1
+ paclitaxel
200 mg/m2
day 1 every 21 days for 4 cycles
carboplatin

AUC 5

day 1

+

gemcitabine

1000 mg/m2

days 1 and 8, every 21 days for 4 cycles

carboplatin

AUC 5

day 1

+

pemetrexed

500 mg/m

day 1 for nonsquamous every 21 days for 4
cycles

2

4.1.2. Incubation Time
In most in vitro cytotoxicity studies, cells are exposed to drug for 48- or 72-hour
continuous exposure (Larsson et al., 2020; Nordin et al., 2019). In fact, many small molecule
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drugs are metabolized or eliminated quickly, so that their half-life in plasma is much shorter than
48 hours. Therefore, it is irrational to use 48- or 72-hour continuous treatment for all drugs and
important to consider the PK of a drug when designing experiments to treat MCS with the drug.
Take cisplatin as an example, the peak plasma concentration is about 10 µM and its half-life is
less than 1 hour in patients (Himmelstein et al., 1981). A rational experimental design with
cisplatin would be to incubate cells with low concentrations for only a few hours instead of using
100 µM and with incubations of 24-72 h (C. Wang & Youle, 2012).
In this study, because it is exceedingly cumbersome for a cell culture system to precisely
mimic the exponential decrease of the drug concentration as we see in the in vivo PK, an
approximation of the PK was simulated by lowering the concentration to ¼ of the original after
two half-lives, and then from ¼ of the original concentration to 0 after another 2 half-lives.
4.2.

Materials and Methods

4.2.1. Materials
A549-iRFP cell line was purchased from Imanis Life Sciences (MN, US). DMEM,
Collagen, Trypsin-EDTA, 1% penicillin-streptomycin were purchased from Thermo-Fisher.
Puromycin was purchased from Alfa Aesar (MA, US). Fetal bovine serum was purchased from
Gemini Bio-Products (CA, US). White Flat Bottom 96-well microplate and 96-well Spheroid
microplate were purchased from Corning Life Science (NY, US). CellTiter-Glo® 3D Cell
Viability Assay kits were purchased from Promega Corporation (Madison, WI, US). Carboplatin
was purchased from ChemScene llc (NJ, US). Gemcitabine Hydrochloride was purchased from
LC Laboratory (MA, US).
4.2.2. Cell Culture Maintenance
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A549-iRFP was maintained in DMEM supplemented with 10% fetal bovine serum
(Gemini, CA, US), 1% Penicillin-Streptomycin (Corning Life Science, NY, US) and 1 μg/ml
puromycin (Alfa Aesar, MA, US). Cells were grown in 5% CO2 at 37 °C and passaged at 85%
confluence every 3~4 days.
4.2.3. 3D MCS
A549-iRFP cells were seeded at 5000 cells/well onto Corning 96-well spheroid
microplates (Corning Life Science, NY, US) to form MCS as described previously (Chapter II
2.2.3). Spheroids were ready for experiment when the diameter reached 500 μm, typically in
5~6 days. At the beginning of the drug treatment, the growth media were replaced by drug
solutions in media. Besides drug treatment, media was partially exchanged every other day by
replacing 100 µl/well media in microplates with 100 µl/well fresh media to ensure a total media
volume of 200 µl.
4.2.4. Scheduled Treatment of MCS with Anticancer Drugs
4.2.4.1.

Targeted levels of drug exposure based on clinical regimen. Among all

the regimens NCCN recommend, carboplatin AUC=5 on day 1, gemcitabine 1000 mg/m2 on
days 1 and 8, every 21 days for 4 cycles was chosen to be mimicked on MCS because both drugs
are in the list of the anticancer drugs under this thesis’ studies.
4.2.4.2.

Grouping. Experimental groups were designed following the criteria

discussed below. Control groups were also prepared for each drug/drug combination per
treatment duration. The grouping details are listed in Table 7.
4.2.4.3.

Duration of drug exposure. Based on our previous lab experience, MCS

has been cultured for 20 days (Yingbo, 2019). So, in this study, the total selected time frame of
drug treatment on MCS was 28 days which is 7 days/cycle, 4 cycles in total, instead of 21 days x
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4 cycles = 84 days for the clinical regimen. Each cycle for the MCS treatment is 7 days, where
carboplatin was given on day 1 of each cycle and gemcitabine on day 1 and day 3 of each cycle.
In order to mimic drug concentration decrease due to metabolism and elimination, some groups
of MCS were scheduled to have media change according to half-life of the drug. Specifically,
the drug concentration was lowered to ¼ of the original after 2 half-lives, and then further
lowered to 0 after another 2 half-lives. Half-lives of gemcitabine and carboplatin are considered
1 hour and 2 hours, respectively, according to prior PK studies (Eli Lilly, 1996; van der Vijgh,
1991). For comparison to the PK-based, cycled drug exposure, additional groups of MCS were
also continuously exposed to drug(s) for 48 hours. The schematic diagram of concentration
changes is shown in Figure 9.
4.2.4.4.

Drug Concentration. The concentration of the drugs to treat MCS are

determined based on two criteria. One criterion is to use clinically relevant concentrations.
According to NCCN guideline, carboplatin is dosed to target AUC=5, which corresponds to 44.65
μM initial concentration for groups that are treated in cycles according to the drug half-life, or
corresponds to 4.65 μM in case of 48-hour continuous drug exposure. Gemcitabine’s initial
concentration is based on its peak plasma concentration (PPC) of about 30 μM when dosed at 1000
mg/m2 (Ciccolini, Serdjebi, Peters, & Giovannetti, 2016). The other criterion is to use IC50 values
of different drugs on the monolayer cells which obtained from the in vitro studies of this thesis.
Therefore, 150 μM was used on carboplatin.
To start the treatment of MCS with a drug, the media (200 µl/well) in microplates was
replaced by 200 µl/well freshly made drug solutions in media.

In order to decrease the

concentration of a single drug to ¼ of the initial level at the double half-life time, 150 of 200 µl
drug-containing media in each well was replaced by fresh, drug-free media. To mimic the PK for
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a two-drug combination, assuming gemcitabine and carboplatin is evenly distributed in the media,
so 150 µl of the initial 200 µl drug-containing media was replaced by freshly prepared, more
diluted carboplatin solution in media at gemcitabine’s first and second half-life so that the
concentration of each of the two drugs in the combination reaches the target concentration. At the
end of drug exposure, all drug-containing media was replaced by fresh, drug-free media (see Table
8).
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Table 8
Detailed Grouping Information and Scheme of Treatment Action
group
number

treatment criteria

drug

concentration
1
2

AUC=5

IC50

5

gemcitabine

PPC

6
7

8

gemcitabine
carboplatin
gemcitabine

PPC
AUC=5
PPC

carboplatin

AUC=5

9

10
control
groups

t1/2
continuous
exposure

4
experimental
groups

t1/2
continuous
exposure

carboplatin

3

duration

-

0

t1/2
continuous
exposure
continuous
exposure

t1/2

follow group
1 and 3 (t1/2
of
carboplatin)
follow group
2 and 4
(continuous
exposure)

11

follow group
5 (t1/2 of
gemcitabine)

12

follow group
6 and 7
(continuous
exposure)

treatment action

44.65 μM carboplatin for 2 carboplatin
half-life (4 hours), then 11.16 μM for
another 2 carboplatin half-life (4
hours)
4.65 µM carboplatin for 48 hours
150 μM carboplatin for 2 carboplatin
half-life (4 hours), then 37.5 μM for
another 2 carboplatin half-life (4
hours)
150 µM carboplatin for 48 hours
30 μM gemcitabine for 2 gemcitabine
half-life (2 hours), then 7.5 μM for
another 2 gemcitabine half-life (2
hours)
30 µM gemcitabine for 48 hours
30 µM gemcitabine and 4.65 μM
carboplatin co-treat for 48 hours
30 μM gemcitabine and 44.65 μM
carboplatin for 2 gemcitabine/ 1
carboplatin half-life (2 hours), then 7.5
μM gemcitabine and 22.33 μM
carboplatin for another 2 gemcitabine
half-life (2 hours), followed with 11.16
μM carboplatin for 2 carboplatin halflife (4 hours)
change media at 2nd carboplatin halflife (4 hours), then incubate for
another 2 carboplatin half-life (4
hours)
incubate for 48 hours
change media at 2nd gemcitabine halflife (2 hours), then incubate for
another 2 gemcitabine half-life (2
hours)
incubate for 48 hours
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(Table 8 Continued)
13

follow group
8 (t1/2 of
gemcitabine
and
carboplatin)

change media at 2nd gemcitabine halflife (2 hours), incubate for another 2
gemcitabine half-life (2 hours)
followed, then change media again
after 2 carboplatin half-life (4 hours)
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Figure 9. Schematic diagram of concentration changes. (A). continuous exposure group; (B).
PK-mimetic carboplatin group; (C) PK-mimetic gemcitabine group; (D) PK-mimetic
combination group.

4.2.4.5.

Viability. The fluorescent signal (λex =685 nm, λem = 700 nm) of the near-

infrared fluorescent protein iRFP from A549-iRFP was recorded by an Odyssey® Infrared
Imaging 205 System (LI-COR® Biosciences, Lincoln, NE, USA) at the 700 nm channel to
measure the iRFP expression as a dynamic indicator of MCS viability. On the last day of
viability monitoring, all the MCS were also assessed by the CellTiter-Glo® 3D Cell Viability
Assay, which measures the cellular ATP level.
The iRFP level and the cellular ATP level of MCS on the last day of viability monitoring
were used to calculate the iRFP inhibition rate and the cellular ATP inhibition rate using the
following equations:
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𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖 𝑖𝑖𝑖𝑖ℎ𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖 𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟 =

𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖 𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙 (𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑−𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡 𝑔𝑔𝑔𝑔𝑔𝑔𝑔𝑔𝑔𝑔)
× 100%
𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖 𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙(𝑐𝑐𝑐𝑐𝑐𝑐𝑡𝑡𝑟𝑟𝑟𝑟𝑟𝑟 𝑔𝑔𝑔𝑔𝑔𝑔𝑔𝑔𝑔𝑔)

𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 𝐴𝐴𝐴𝐴𝐴𝐴 𝑖𝑖𝑖𝑖ℎ𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖 𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟 =

𝐴𝐴𝐴𝐴𝐴𝐴 𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙(𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑−𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚 𝑔𝑔𝑔𝑔𝑔𝑔𝑔𝑔𝑔𝑔)
× 100%
𝐴𝐴𝐴𝐴𝐴𝐴 𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙(𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 𝑔𝑔𝑔𝑔𝑔𝑔𝑔𝑔𝑔𝑔)

Equation 4.1

Equation 4.2

4.2.5. Data Analysis
Data are presented as mean ± standard deviation (SD). When there were more than two
groups, the statistical analysis was performed by Brown-Forsythe and Welch one-way analysis
of variance (ANOVA) using GraphPad Prism 8.0 Software. Tamhane’s T2 multiple
comparisons test analysis was performed to compare between groups, unpaired t-test was
performed when there were only two groups to compare. Results with P < 0.05 were accepted as
statistically significant.
4.3.

Results and Discussion

4.3.1. A549-iRFP MCS’s Response to Carboplatin
Figure 10 shows the growth curves of carboplatin treated MCS as shown by the increase
of the iRFP fluorescence. Viability of MCS on the last day was extracted from Figure 10 and
plotted in Figure 11 (A). The inhibition of viability (Figure 11 B) was calculated from the iRFP
level of the last day, where the iRFP level of a treatment group was divided by the iRFP level
from its drug-free control group (Equation 4.1). 3D viability assay was also used to
independently validate the iRFP-based MCS viability and plotted in Figure 11 (C). The data in
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Figure 13 (C) was extracted and used to calculate the inhibition of viability according to the 3D
viability assay of cellular ATP (Figure 11 D, Equation 4.2).

Figure 10. Growth curves of carboplatin treated MCS, according to the fluorescence of cellular
iRFP.

Figure 11. Viability and inhibition rate of carboplatin-treated A549-iRFP MCS. Data presented
as mean ± SD, N ≥4. (A) Viability by iRFP level; (B) Inhibition rate calculated from iRFP level;
(C) Viability by cellular ATP level using CellTiter-Glo® 3D Cell Viability Assay; (D) Inhibition
rate calculated from cellular ATP. **P< 0.002, ****P<0.0001 for Brown-Forsythe and Welch
ANOVA.

There is no statistic difference (P>0.05 by Brown-Forsythe and Welch ANOVA) between
two drug-free control groups (both treated with drug-free media, one incubated for 48 hours, one
changed media according to half-life) in Figure 11 (A, C), indicating changing media at half-live
doesn’t affect MCS viability. The 150 µM, 48-hour treatment group statistically inhibited more
cell growth (P<0.05 by Brown-Forsythe and Welch ANOVA) than 150 µM, PK simulation
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group in Figure 11 (A-D). Even though these two groups share the same concentration, they
have different treatment duration, which resulted in different inhibition effect. Continuous drug
exposure for 48-hour or 72-hour is commonly used in many cell culture assays for drugscreening. However, most drugs metabolize quickly in body and thus does not maintain the
initial concentration at the site of action for 48 hours to 72 hours. Therefore, changing media to
mimic the decrease of drug concentration in vivo would improve the clinical relevance of drug
screening in cell culture. The 4.65 µM, 48-hour treatment group inhibit a little bit more than
44.65 µM, PK simulation group, but the difference is not statistically significant (P>0.05 by
Brown-Forsythe and Welch ANOVA, Figure 11 A-D). Although these two groups were treated
with different concentrations and duration of drug exposure, they had the same AUC. Their
similar viability inhibition rates indicate that neither longer duration of drug exposure nor higher
drug concentration is superior. The similar viability inhibition also suggest that AUC is a better
predictor of the efficacy of carboplatin. Results in Figure 11 A, B are consistent with Figure 11
C, D, indicating that, similar to cellular ATP level, the iRFP fluorescent signal is a reliable
indicator of MCS growth and viability. It also very convenient and can be assessed repeatedly,
whereas by measuring ATP level, MCS will have to be sacrificed. However, large standard
deviations are seen using iRFP signal shown in Figure 10. This is probably because the media
change sometimes moved MCS off the center in a well, which increased the absorption of the
fluorescent signal by the black wall of the 96-well plate, which in turn artificially lowered the
reading and increased the g variances. According to drug responses from MCS, it shows that
MCS can be used in intensive and long-term cytotoxicity study.
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4.3.2. A549-iRFP MCS’s Response to Gemcitabine
Figure 12 shows the growth curves of gemcitabine treated MCS, as indicated by the
change of viability determined by the fluorescence of cellular iRFP. Moreover, viability of MCS
on the last day of the experiment was re-plotted in Figure 13 A. Figure 13A is then re-plotted in
Figure 13 B, where the decrease of iRFP fluorescence was divided by the iRFP fluorescence of
control MCS that were not exposed to the anticancer drug to indicate growth inhibition (Equation
4.1). For cross-validation, cellular ATP of MCS at the end of the experiment was also measured
by the 3D viability assay (Figure 13 C) and re-plotted into growth inhibition in Figure 13 D by
dividing the decrease of cellular ATP with that of control MCS (Equation 4.2).

Figure 12. Growth curves of gemcitabine treated A549iRFP MCS, according to the fluorescence
of cellular iRFP.
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Figure 13. Viability and inhibition rate of gemcitabine-treated A549-iRFP MCS. Data presented
as mean ± SD, N ≥4. (A) Viability indicated as iRFP level; (B) Inhibition rate calculated from
iRFP level; (C) Viability read by CellTiter-Glo® 3D Cell Viability Assay; (D) Inhibition rate
calculated from 3D cell viability assay. **P< 0.002, ****P<0.0001 for Brown-Forsythe and
Welch ANOVA. ++P< 0.002, ++++P<0.0001 for unpaired t test.
There is no statistic difference (P>0.05 by Brown-Forsythe and Welch ANOVA) between
the two drug-free control groups (both treated with drug-free media, one incubated for 48 hours,
one changed media according to half-life) in Figure 13 (A, C), indicating that changing media at
the half-live time points did not affect the MCS viability. Gemcitabine that was treated at 30 µM
for 48- inhibit most cell growth in this study, which is not consistent with IC50 viability curve
done in Chapter III. In this case, it is almost complete inhibition whereas in previous scenario,
none can inhibit more than 50%. This could probably relate to batch difference of gemcitabine.
The 30 µM, 48-hour treatment group shows statistically lower viability (P<0.05 by BrownForsythe and Welch ANOVA) than the 30 µM, PK simulation group in Figure 13 (A, C)
according to iRFP fluorescence, which is consistent with the significantly different cellular ATP
levels between the two groups (Figure 13 B and D), both strongly indicating that continuous drug
exposure over 48 hours inhibited MCS viability significantly more (P<0.05 by Brown-Forsythe
and Welch ANOVA) than pulsed exposure according to the drug’s PK in vivo. This
phenomenon is also consistent with what is seen in carboplatin treated MCS groups (Figure 11).
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Similar to results on carboplatin-treated MCS groups (Figure 10), reproducible and easily
assessed iRFP signal shows relatively large standard deviations in gemcitabine-treated MCS
(Figure 12). Furthermore, MCS show sensitive drug responses, this indicates its ability to be
used in intensive, long-term cytotoxicity study.
4.3.3. Response of A549-iRFP MCS to Drug Combinations
Figure 14 shows the growth curves of MCS that are treated with a combination of
carboplatin and gemcitabine based on the fluorescence of cellular iRFP. Viability of such MCS
on the last day was re-plotted in Figure 15 A, from which growth inhibition was derived (Figure
15 B) by dividing the decrease of iRFP fluorescence with iRFP fluorescence of control MCS that
was not exposed to any drug (Equation 4.1). The 3D viability assay based on cellular ATP
measurements was also used to cross-validate the MCS viability (Figure 15 C), from which
growth inhibition was derived (Figure 15 D) by dividing the decrease of cellular ATP with that
of control MCS that was not exposed to any drug (Equation 4.2).

Figure 14. Growth curves of MCS treated with a combination of carboplatin and gemcitabine
according to the fluorescence of cellular iRFP.
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Figure 15. Viability and inhibition rate of carboplatin and gemcitabine-treated A549-iRFP MCS.
Data presented as mean ± SD, N ≥4. (A) Viability indicated as iRFP level; (B) Inhibition rate
calculated from iRFP level; (C) Viability read by CellTiter-Glo® 3D Cell Viability Assay; (D)
Inhibition rate calculated from 3D cell viability assay. **P< 0.002, ****P<0.0001 for BrownForsythe and Welch ANOVA. ++P< 0.002, ++++P<0.0001 for unpaired t test.
There is statistically significant difference (P<0.05 by Brown-Forsythe and Welch
ANOVA) between drug-free control groups of 48-hour and the one that changes media
according to gemcitabine and carboplatin’s half-life. The lower viability in the PK simulation
group in Figure 15 (A, C) is probably related to the fact that PK simulation group had media
changes three times as often as the continuous exposure control group. This result indicates that
the more time the media is changed the more MCS viability is affected negatively. Statistic
difference (P<0.05 by Brown-Forsythe and Welch ANOVA) is also seen between MCS under
continuous exposure to 30 µM gemcitabine plus 4.65 µM carboplatin group and MCS under
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half-life-based exposure to 30 µM gemcitabine plus 44.65 µM carboplatin group, as shown in
Figure 15 (A, C). The continuous-exposure group has lower viability comparing to PK mimetic
group, which is consistent with the finding in single carboplatin and single gemcitabine group
(Figure 11 B, D and Figure 13 B, D). By changing media at half-lives, although this is not a
perfect mimetic of PK changes, it still reduces positive bias from 48-hour or 72-hour continuous
exposure and gives us a brief insight of how drugs will work in vivo. Results in Figure 15 A and
B are consistent with Figure 15 C and D, indicating that the iRFP fluorescent is a reliable signal
to monitor MCS growth. Large standard deviations can also be seen in Figure 16. Similar to
results on carboplatin-treated MCS and gemcitabine-treated MCS, MCS co-treated with
carboplatin and gemcitabine shows good viability response at the end of this study, and is able to
under through intense dosing schedule, indicating its promising future in long-term cytotoxicity
study.
4.4.

Summary

MCS of the fluorescent lung cancer cell line A549 iRFP have been treated with
chemotherapy agents not only by continuous exposure, but also by schedules that mimic the drug
pharmacokinetics and the clinical chemotherapy regimen. A number of conclusions can be
drawn from this study. Firstly, MCS can be cultured for more than 30 days while under
complicated drug treatment. Secondly, all continuous drug exposure inhibited more cell growth
than the corresponding PK-simulating drug exposure. Thirdly, changing media at half-lives can
simulate the drug PK roughly. Even though it is not a perfect simulation, it better reflects the
drug efficacy, especially when comparing drugs of different half-lives. If only continuous drug
exposure is used to assess anticancer activity, it would bring bias for the potency of certain drugs
over others. Fourthly, all cell viability/growth inhibition results based on the near-infrared signal
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of the fluorescent cellular protein iRFP is consistent with the luminescent signal of cellular ATP
in the 3D viability assay. The fluorescent signal of iRFP can be measured multiple times over
the long course of the experiment without sacrificing the MCS and thus can provide the dynamic
data of MCS growth. However, the fluorescent signals carry large standard deviations. To
improve the data precision in future study, extra attention is needed to make sure that MCS is
still placed in the center of the well after each media change.
Overall, dynamic treatment of MCS with anticancer drugs based on drug PK and clinical
regimen can be used as platform in drug discovery.
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